Cancer Treatment Market Research Reports & Industry Analysis
Cancer is a disease characterized by uncontrolled cell proliferation. Of the more than 100 types of cancer, lung, breast, and colorectal cancer account for nearly half of new cases per year in the United States. Lung cancer, which is highly correlated with cigarette smoking, is responsible for more deaths than any other form of cancer. Cigarette smoking and other environmental factors are associated with the majority of cancers.
With the growing incidence of cancer, a growing and aging world population and significant medical advances, there will continue to be phenomenal growth in the market for cancer diagnosis and treatment products.
Cancer Treatment Industry Research & Market Reports
-
Dendritic Cell Cancer Vaccines
... 2030, growing at a CAGR of 13.0% over the analysis period 2024-2030. Sipuleucel-T Vaccines, one of the segments analyzed in the report, is expected to record a 14.7% CAGR and reach US$987.7 Million by the ... Read More
-
Pancreatic Cancer Diagnostic
... at a CAGR of 5.4% over the analysis period 2024-2030. Pancreatic Cancer Diagnostic Consumables, one of the segments analyzed in the report, is expected to record a 6.6% CAGR and reach US$2.1 Billion by the ... Read More
-
Bladder Cancer Treatment Drugs
... 2030, growing at a CAGR of 14.5% over the analysis period 2024-2030. Immunotherapy Drugs, one of the segments analyzed in the report, is expected to record a 15.2% CAGR and reach US$4.8 Billion by the ... Read More
-
Leukemia Screening
... CAGR of 5.6% over the analysis period 2024-2030. Complete Blood Count, one of the segments analyzed in the report, is expected to record a 5.9% CAGR and reach US$2.7 Billion by the end of the ... Read More
-
Hyperthermia Cancer Treatment
... at a CAGR of 4.8% over the analysis period 2024-2030. Local Hyperthermia, one of the segments analyzed in the report, is expected to record a 4.6% CAGR and reach US$141.9 Million by the end of ... Read More
-
Gastric Cancer
... CAGR of 16.9% over the analysis period 2024-2030. Adenocarcinoma, one of the segments analyzed in the report, is expected to record a 14.8% CAGR and reach US$2.4 Billion by the end of the analysis period. ... Read More
-
Cervical Cancer Endoscopic Devices
... 2030, growing at a CAGR of 3.3% over the analysis period 2024-2030. Optical Colposcopes, one of the segments analyzed in the report, is expected to record a 2.9% CAGR and reach US$668.1 Million by the ... Read More
-
Non-Small Cell Lung Cancer (NSCLC) Therapeutics
... reach US$54.0 Billion by 2030, growing at a CAGR of 8.7% over the analysis period 2024-2030. Targeted Therapy, one of the segments analyzed in the report, is expected to record a 9.7% CAGR and reach ... Read More
-
Cancer Biomarkers
... CAGR of 16.9% over the analysis period 2024-2030. Protein Biomarkers, one of the segments analyzed in the report, is expected to record a 17.4% CAGR and reach US$42.9 Billion by the end of the analysis ... Read More
-
Cancer Immunotherapy
... CAGR of 13.7% over the analysis period 2024-2030. Monoclonal Antibodies, one of the segments analyzed in the report, is expected to record a 14.5% CAGR and reach US$266.2 Billion by the end of the analysis ... Read More
-
Cancer Stem Cells
... at a CAGR of 8.5% over the analysis period 2024-2030. Stem Cell-based Cancer Therapy, one of the segments analyzed in the report, is expected to record a 7.9% CAGR and reach US$1.3 Billion by the ... Read More
-
Colposcopy
... 3.9% over the analysis period 2024-2030. Cervical Cancer Screening, one of the segments analyzed in the report, is expected to record a 4.2% CAGR and reach US$440.5 Million by the end of the analysis period. ... Read More
-
Skin Cancer Diagnostics
... at a CAGR of 3.8% over the analysis period 2024-2030. Melanoma, one of the segments analyzed in the report, is expected to record a 3.0% CAGR and reach US$7.0 Billion by the end of the ... Read More
-
Multi Cancer Early Detection
... 2030, growing at a CAGR of 15.6% over the analysis period 2024-2030. Gene Panel & LDT, one of the segments analyzed in the report, is expected to record a 13.8% CAGR and reach US$1.4 Billion ... Read More
-
Cancer Treatment Facilities
... at a CAGR of 7.0% over the analysis period 2024-2030. Cancer Surgery, one of the segments analyzed in the report, is expected to record a 7.7% CAGR and reach US$41.0 Billion by the end of ... Read More
-
Bone Cancer Treatment
... at a CAGR of 2.9% over the analysis period 2024-2030. Osteosarcoma, one of the segments analyzed in the report, is expected to record a 3.3% CAGR and reach US$880.4 Million by the end of the ... Read More
-
Fallopian Tube Cancer Therapeutics
... 2030, growing at a CAGR of 10.7% over the analysis period 2024-2030. Targeted Therapy, one of the segments analyzed in the report, is expected to record a 11.7% CAGR and reach US$2.2 Billion by the ... Read More
-
Cancer Active Pharmaceutical Ingredients (APIs)
... Billion by 2030, growing at a CAGR of 3.9% over the analysis period 2024-2030. Innovative Type, one of the segments analyzed in the report, is expected to record a 3.2% CAGR and reach US$38.4 Billion ... Read More
-
Skin Cancer Drugs
... at a CAGR of 6.8% over the analysis period 2024-2030. Chemotherapy Drugs, one of the segments analyzed in the report, is expected to record a 7.0% CAGR and reach US$5.3 Billion by the end of ... Read More
-
Oropharyngeal Cancer Diagnosis and Therapeutics
... Billion by 2030, growing at a CAGR of 8.3% over the analysis period 2024-2030. Endoscopy, one of the segments analyzed in the report, is expected to record a 10.2% CAGR and reach US$859.7 Million by ... Read More
-
Gallbladder Cancer
... CAGR of 2.9% over the analysis period 2024-2030. Surgery, one of the segments analyzed in the report, is expected to record a 2.2% CAGR and reach US$20.1 Million by the end of the analysis period. ... Read More
-
Lung Cancer Treatment
... at a CAGR of 7.6% over the analysis period 2024-2030. NSCLC Cancer Type, one of the segments analyzed in the report, is expected to record a 6.2% CAGR and reach US$46.2 Billion by the end ... Read More
-
Oncology Based In-Vivo CRO
... 2030, growing at a CAGR of 7.0% over the analysis period 2024-2030. Solid Tumors, one of the segments analyzed in the report, is expected to record a 7.0% CAGR and reach US$1.2 Billion by the ... Read More
-
Cancer Registry Software
... at a CAGR of 9.6% over the analysis period 2024-2030. Standalone, one of the segments analyzed in the report, is expected to record a 9.3% CAGR and reach US$116.6 Million by the end of the ... Read More
-
Antineoplastic Agents
... CAGR of 7.3% over the analysis period 2024-2030. Chemotherapeutic Agents, one of the segments analyzed in the report, is expected to record a 6.9% CAGR and reach US$137.9 Billion by the end of the analysis ... Read More
Research Assistance
